Get the Stockscreener App
7.75
1.04%
0.08
After Hours:
7.75
Ocular Therapeutix Inc Stock (OCUL) Latest News
Why Investors Shouldn't Be Surprised By Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) P/S - Simply Wall St
Open Angle Glaucoma Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Visiox Pharma, TearClear, VivaVision Biotech, Inc., Abbvie, Ocuphire Pharma, Qlaris Bio, Inc - The Globe and Mail
What 4 Analyst Ratings Have To Say About Ocular Therapeutix - Benzinga
RBC Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation - Nasdaq
Ocular's Axpaxli May Take Wet AMD Market Share, RBC Says -March 18, 2025 at 11:38 am EDT - Marketscreener.com
RBC Initiates Ocular Therapeutix at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com
Ocular rises as Needham issues new Buy on lead candidate - MSN
When (OCUL) Moves Investors should Listen - Stock Traders Daily
Ocular Therapeutix (OCUL) Stock Movement Driven by Analyst Cover - GuruFocus.com
Why Ocular Therapeutix Was Bumping Higher This Week - Yahoo
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - AOL
Ocular Therapeutix (NASDAQ:OCUL) Now Covered by Analysts at Needham & Company LLC - Defense World
Head-To-Head Review: Corcept Therapeutics (NASDAQ:CORT) vs. Ocular Therapeutix (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside - AOL
Needham Initiates Ocular Therapeutix at Buy With $15 Price Target -March 11, 2025 at 07:30 am EDT - Marketscreener.com
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Needham Initiates Coverage of Ocular Therapeutix (OCUL) with Buy Recommendation - Nasdaq
Ocular Therapeutix initiated with a Buy at Needham - TipRanks
Ocular Therapeutix at Leerink Conference: Strategic Insights on XPAXLI By Investing.com - Investing.com Canada
Ocular Therapeutix at Leerink Conference: Strategic Insights on AXPAXLI By Investing.com - Investing.com Australia
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ocular Therapeutix Awards Stock Options and RSUs to New Employee - StockTitan
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
HC Wainwright Has Pessimistic Outlook of OCUL Q1 Earnings - Defense World
Ocular Therapeutix: Axpaxli’s Dual Trial Strategy And Blockbuster Potential - Seeking Alpha
Ocular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from HC Wainwright - Defense World
Ocular Therapeutix, Inc. to Host Earnings Call - ACCESS Newswire
Ocular Therapeutix outlines AXPAXLI NDA submission timeline with SOL-1 topline data expected Q1 2026 - MSN
Truist Financial Corp Acquires Shares of 50,000 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Traders Purchase High Volume of Call Options on Ocular Therapeutix (NASDAQ:OCUL) - Defense World
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus.com
Diabetic Retinopathy Pipeline 2025: Mechanism of Action, Route - openPR
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2024 Earnings Call Transcript - Insider Monkey
Ocular Therapeutix price target lowered to $19 at Citizens JMP, buy on weakness - TipRanks
Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... By GuruFocus - Investing.com Canada
New York State Common Retirement Fund Boosts Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback - MSN
Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down Following Weak Earnings - Defense World
Ocular Therapeutix Inc. Faces Operational Risks Amid Regulatory Delays and Government Disruptions - TipRanks
Ocular Therapeutix Reports Fourth Quarter and Full Year 2024 Revenue Growth - Vision Monday
Ocular Therapeutix Reports 2024 Financial Results and Progress - TipRanks
Ocular Therapeutix Earnings Call Highlights Progress and Challenges - TipRanks
Ocular Therapeutix: Q4 Earnings Snapshot - CTPost
Ocular Therapeutix Inc earnings missed by $0.04, revenue fell short of estimates - Investing.com South Africa
Earnings call transcript: Ocular Therapeutix Q4 2024 misses EPS forecast - Investing.com India
Earnings call transcript: Ocular Therapeutix Q4 2024 misses EPS forecast By Investing.com - Investing.com Australia
BofA cuts Ocular Therapeutix target to $17, maintains buy By Investing.com - Investing.com UK
Ocular Therapeutix shares tumble on earnings miss By Investing.com - Investing.com South Africa
Ocular Therapeutix shares tumble on earnings miss - Investing.com
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates - MSN
Ocular Therapeutix Shares Drop After Wider-Than-Expected 4Q Loss - MarketWatch
Ocular Therapeutix Inc reports results for the quarter ended December 31Earnings Summary - TradingView
1.46%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):